The past 12 months haven't been kind to investors in Illumina (NASDAQ:ILMN). Shareholders of the genomic-sequencing equipment maker have endured a sickening decline of more than 33%, which vastly underperforms both the broader biotech industry as well as the S&P 500.
Is the future finally looking up for shareholders, or could the slide continue from here? Let's take a look at the year's key developments to figure out which is more likely.
Why it's been a rough year
The dismal forecast caused many analysts to reevaluate the company's prospects. Some analysts are even projecting that Illumina's weak numbers will persist for several more quarters due to increased competition from companies like Thermo Fisher Scientific. That fear has led to several price target revisions, further weighing down the company's stock.
When you combine the barrage of bad news with the stock's premium valuation, it is easy to understand why Illumina's shares have been under pressure all year.
Here's why we could be near the bottom
Despite all the doom and gloom, there are reasons to believe that the selling pressure could be nearing an end.
First, while Illumina did miss on its third-quarter revenue guidance, it only came up 3% short of its forecast. In addition, the $607 million in revenue still represented double-digit growth over the third quarter of 2015. Illumina's non-GAAP EPS of $0.97 was also much better than the $0.87 that analysts were expecting. While these figures are a bit disappointing, they do not imply that the company is falling apart.
Second, Illumina's management team doesn't believe that the revenue miss was caused by competition. Here's a choice quote from deSouza on the company's earnings call with investors:
Since the close of the quarter, we have analyzed market and funding dynamics, capacity utilization, competition, and outsourcing trends. Based on these reviews, we do not believe that excess market capacity, outsourcing, or competition materially affected our results or outlook.
He also later noted that the company's win rate continues to hold steady. That implies that Illumina continues to have a leg up over competitors.
Third, Illumina continues to invest heavily in its future. The company's two moonshot initiatives -- Helix and Grail -- offered the potential to open up a $100 billion market opportunity. While we are still years away from that happening, these projects do provide investors with a reason to remain optimistic.
Finally, while Illumina's trailing P/E ratio of 43 isn't classically "cheap," it is one of the lowest valuations that shares have fetched over the last few years.
Have we reached a bottom?
While it would be small "f" foolish to call a bottom in any growth stock that still trades at a premium valuation, I can't help but feel that the market's reaction to Illumina's 2016 might be overdone. After all, Illumina is still the top dog in an important and emerging industry, and if Helix or Grail pay off, the company's future could be extremely bright. Still, it is notoriously difficult to value growth companies that promise game-changing technology, so I could easily see plenty more volatility ahead.
If you are bullish on Illumina today, the smart move might be to open up a small position and then add more on any future declines.
Brian Feroldi has no position in any stocks mentioned. Like this article? Follow him on Twitter where he goes by the handle @Longtermmindset or connect with him on LinkedIn to see more articles like this.
The Motley Fool owns shares of and recommends Illumina. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Better Buy: Illumina, Inc. vs. Thermo Fisher Scientific
Which stock wins in a head-to-head match-up between these two gene-sequencing leaders?
Is Illumina, Inc. a Buy?
The company's stock has had huge gains this year. Is it too late to get in?
Better Buy: Illumina, Inc. vs. Pacific Biosciences
One of these vendors of gene sequencing instruments is flexing its muscles and the other is struggling.